Abstract
The authors present a 10-year-old girl with tuberous sclerosis complex who has been receiving rapamycin for 10 months for seizure control. She was started at 0.05 mg/kg/d and titrated to an effective dose of 0.15 mg/kg/d. There was a dramatic reduction in seizure frequency with rapamycin therapy. Further studies are needed to objectively investigate the benefits of rapamycin in tuberous sclerosis complex and to clarify its mechanism of seizure control.
MeSH terms
-
Anticonvulsants / administration & dosage*
-
Anticonvulsants / adverse effects
-
Carbamazepine / analogs & derivatives
-
Carbamazepine / therapeutic use
-
Cerebral Cortex / drug effects
-
Cerebral Cortex / pathology
-
Cerebral Cortex / physiopathology
-
Child
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Fructose / analogs & derivatives
-
Fructose / therapeutic use
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects
-
Magnetic Resonance Imaging
-
Neurosurgical Procedures
-
Paresis / etiology
-
Paresis / physiopathology
-
Seizures / drug therapy*
-
Seizures / etiology*
-
Seizures / physiopathology
-
Sirolimus / administration & dosage*
-
Sirolimus / adverse effects
-
Topiramate
-
Treatment Outcome
-
Tuberous Sclerosis / complications*
-
Tuberous Sclerosis / pathology
-
Tuberous Sclerosis / physiopathology
-
Virus Diseases / chemically induced
-
Virus Diseases / immunology
Substances
-
Anticonvulsants
-
Immunosuppressive Agents
-
oxcarbamazepine
-
Topiramate
-
Fructose
-
Carbamazepine
-
Sirolimus